PRR have a lot of potential, but it's very long term. There's others who are better investments atm, imho.
Market caps:
PRR $195m.
ACL $121m (large near term revenues, phase 3 trial to start soon too).
TIS $92m (commercialisation within months).
NEU $13m (two phase 2 trials running, both funded by third parties).
PRR became a darling because the sp kept rising. That adds fuel to the belief in the company. There's nothing wrong with that belief, the PRR drug looks great. It's just there is better short term potential elsewhere imho.
Good luck to holders
where to tomorrow, page-46
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
0.005(1.47%) |
Mkt cap ! $501.1M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 32.5¢ | $659.6K | 1.969M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 399004 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 4457 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |